Pro-Dex, Inc.
PDEXHealthcareNASDAQMedical Instruments & Supplies · Last scanned Sep 8, 2026
Scan Results
Daily timeframePro-Dex, Inc. designs, develops, manufactures, and repairs powered surgical instruments for medical device original equipment manufacturers worldwide. The company carries a $235.2M market cap, placing it firmly in the micro-cap category. It offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
Market Cap
$235.2M
Beta
0.06
P/E (TTM)
17.82
P/E (Fwd)
35.64
EPS (TTM)
$4.12
EPS (Fwd)
$2.06
ROE
32.4%
ROA
12.0%
Cash
$9.3M
Total Debt
$18.9M
Free CF
$5.4M
52W Change
101.7%
Annual Financials
Cash vs Debt
Where PDEX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PDEX finished 13.35% above its 150-day moving average ($55.21) and 22.20% above its 200-day moving average ($51.21). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PDEX overbought or oversold?
At the September 3, 2026 close, PDEX's RSI(14) was 28.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $9.3M in cash, though total debt stands at $18.9M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $5.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 32.4% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 12.0% further supports the picture of efficient asset utilization. Revenue has grown from $42.0M (2022) to $66.6M (2025), reflecting a 58% increase over the period.
PDEX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Pro-Dex, Inc.'s trajectory.